Sanofi : No turn-around in sight

● In a short-term perspective, the company has interesting fundamentals.

● The group's activity appears highly profitable thanks to its outperforming net margins.

● This company will be of major interest to investors in search of a high dividend stock.

● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

● The stock is close to a major daily resistance at EUR 87.52, which should be gotten rid of so as to gain new appreciation potential.

● According to forecast, a sluggish sales growth is expected for the next fiscal years.

● The group usually releases earnings worse than estimated.

● For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.